Intel Nears $8B CHIPS Act Grant Deal with Commerce Dept
Intel Corporation and the U.S. Department of Commerce are nearing the finalization of a substantial $8 billion grant under …
Sanofi is ditching the mRNA Covid-19 vaccine after rivals’ success
September 29, 2021: -On Tuesday, Sanofi is dropping plans for its mRNA-based Covid-19 vaccine because of the dominance achieved by BioNTech-Pfizer, and Moderna uses the technology to fight the pandemic, the company said.
The move highlights the challenges of competing with pioneer BioNTech, which rose from obscurity through its alliance with pharma major Pfizer in the previous year. They have delivered close to 1.5 billion doses to become the Western world’s largest Covid-19 vaccine maker.
French healthcare group Sanofi will focus on efforts with British partner GlaxoSmithKline to bring another Covid-19 vaccine candidate to market based on the conventional protein-based approach, where mass trials are ongoing.
On Tuesday, the decision to drop clinical development of a shot based on mRNA, or messenger RNA, acquired as part of its takeover of Translate Bio, came despite positive Phase I/II study interim results announced where participants’ blood readings showed a robust immune reaction.
Sanofi said the read-out encouraged it only to pursue the technology as a potential vaccine against influenza and other diseases, which gives up on the area of Covid-19 because of the strong market presence of the two approved mRNA shots.
“The results are significant as they show us that the platform we acquired works,” Thomas Triomphe, head of the Sanofi Pasteur vaccines division, told journalists. He kicks off final Phase III trials now made no sense.
“Would it be the best use of this wealth of science afforded by mRNA vaccines to make a Covid-19 vaccine and try and bring one more mRNA Covid-19 vaccine to people who already today may not want an mRNA Covid-19 vaccine? Clearly not,” Triomphe said.
He added that by May or June 2022, 24 billion doses of Covid-19 jabs made by different manufacturers would have been delivered, which adds to the disincentives to produce a vaccine candidate when Covid-19 was unlikely to require vaccination based annually, instead of the flu.
Sanofi’s shares were flat at 82.1 euros by 1026 GMT, outperforming a 1.37% not approved in the STOXX Europe 600 Health Care.
“The decision of RNA looks to be interpreted as positive since they will save development costs and concentrate on the different products and ventures,” said Ion-Marc Valahu, a fund manager at Geneva from investment firm Clairinvest.
- Categories: News
About Us
We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.
Recent Posts
Insurtech vs. Traditional Insurance: Why the Old Guard is Fading Fast
Insurtech is not just making waves in the insurance industry—it’s rewriting the rulebook. As technology-driven startups disrupt …
Say Goodbye to Spreadsheet Hell: Why You Need to Try This Accounting Software ASAP
When managing finances, the dreaded spreadsheet has long been a necessary evil. Hours spent painstakingly inputting …
Cochin Shipyard Signs MoU with Seatrium Letourneau, USA
Cochin Shipyard Limited (CSL), a leading shipbuilding and repair company in India, has entered into a …
Bank of America Boosts Netflix Target to $1K on Fight Viewers
Bank of America has raised its price target for Netflix to $1,000 per share, citing the streaming giant’s impressive subscriber growth …
CalFoods Logistics | Making A Difference for those in Need | Steve Linkhart
Steve Linkhart, CEO of CalFoods Logistics, believes that he possesses one quality that sets the tone for CalFoods Logistics. “When we hire a new team member, there are clear responsibilities that need to be accomplished. Once we hire, train, and let that person take the ownership of the job, we allow them to do their job,” he explains. “We are always there to assist of course, but I feel that people get a sense of ownership of their role when they are allowed to do so. Everyone has a role from being CEO to pulling or entering orders, everyone has their unique responsibilities, and the foundation is always customer service, without that, everything after is on shaky ground.” Steve feels that there isn’t a role here too big or too small for anyone to jump in and help. He has unloaded his fair share of trucks and pulled orders over the past 18 months and will be glad to do it again if needed. “Taking care of our team is of the utmost importance to me. We offer a living wage, amazing benefits, and time off for the team to have a good work/life balance.”